General Hospital of Ningxia Medical University
Yinchuan, Ningxia, 750000, China
NCT Number: NCT07663695
Post-induction hypotension (PIH) is a common and critical complication during general anesthesia, particularly in frail elderly patients whose physiological reserves are significantly diminished. PIH is strongly associated with adverse postoperative outcomes, including acute kidney injury (AKI) and myocardial injury. Propofol is the most widely used induction agent but frequently induces circulatory depression. Ciprofol, a novel anesthetic agent developed by optimizing the molecular structure of propofol, has demonstrated improved hemodynamic stability and fewer adverse effects in general populations. However, its specific impact on frail elderly patients remains unestablished.
The primary purpose of this single-center, randomized, double-blind, controlled trial is to compare the effects of propofol and ciprofol during anesthesia induction on the incidence of PIH in frail elderly patients undergoing major abdominal surgery. The investigator's hypothesis is that ciprofol will significantly lower the incidence of PIH compared to propofol. Additionally, the study will evaluate secondary clinical outcomes, such as postoperative AKI, postoperative cardiac complications, and the overall quality of recovery, to provide an evidence-based clinical guide for selecting optimal induction agents for this vulnerable patient population.
Trial opening soon.
Get Notified60 year and older
All sexes
Interventional
Not applicable
Yinchuan, Ningxia, 750000, China
Background and Rationale:
Frail elderly patients exhibit an accumulation of multi-system physiological decline, making them highly vulnerable to surgical and anesthetic stressors. During the induction of general anesthesia, these patients are at an exceptionally high risk for severe and prolonged hypotension due to reduced cardiac stroke volume, impaired autonomic nervous system regulation, and altered pharmacokinetics. Post-induction hypotension (PIH)-occurring from the initiation of anesthesia to 10 minutes post-intubation-is directly influenced by the choice of induction agent and the patient's baseline condition, with fewer confounding factors than intraoperative hypotension.
While propofol is highly efficient, its prominent side effect is cardiovascular depression. Ciprofol is an innovative 2,6-disubstituted phenol derivative that maintains the rapid onset and recovery advantages of propofol while offering enhanced hemodynamic stability. To date, clinical evidence comparing these two agents specifically in the frail elderly population is lacking. This study seeks to evaluate whether ciprofol can mitigate the risk of PIH in frail elderly patients undergoing major abdominal surgery and to observe its downstream impacts on major organ protection and postoperative recovery quality.
Study Workflow and Anesthesia Management:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
An innovative 2,6-disubstituted phenol derivative used for general anesthesia induction.
An alkylphenol derivative and standard intravenous anesthetic agent used for general anesthesia induction.
Time frame: From the initiation of general anesthesia drug administration until 10 minutes after endotracheal intubation.
Post-induction hypotension (PIH) is defined as a mean arterial pressure (MAP) < 65 mmHg lasting for more than 1 minute.
Contact information is provided by the study sponsor or research team.
General Hospital of Ningxia Medical University
Other
Comparison of the Effects of Propofol and Ciprofol on the Incidence of Post-induction Hypotension in Frail Elderly Patients Undergoing General Anesthesia
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07678723
Cardiovascular Diseases, Cesarean Delivery
View Trial DetailsNCT07674511
Autonomic Nervous System Diseases, Blood Pressure
West Orange, New Jersey, United States
View Trial DetailsNCT07613073
Cardiovascular Diseases, Hypotension
Hanoi, Vietnam
View Trial DetailsNCT07565025
Anesthesia, General, Cardiovascular Diseases
Gaziantep, Turkey (Türkiye)
View Trial Details